Rani Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $172 | $1,028 | $0 |
Gross Profit | -240 | 172 | 1,028 | -259 |
EBITDA | -10,505 | -12,013 | -14,332 | -11,126 |
EBIT | -12,264 | -14,598 | -11,385 | |
Net Income | -6,692 | -7,264 | -8,947 | -6,783 |
Net Change In Cash | 0 | 172 | 1,028 | 0 |
Free Cash Flow | -5,833 | -8,199 | -8,686 | -8,535 |
Cash | 10,216 | 10,111 | 3,762 | 4,277 |
Basic Shares | 36,542 | 33,440 | 32,660 | 28,836 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,028 | $0 | $0 | $2,717 |
Gross Profit | 1,028 | -822 | -1,312 | 2,717 |
EBITDA | -50,523 | -65,277 | -60,891 | -52,084 |
EBIT | -51,551 | -66,099 | -62,203 | -52,581 |
Net Income | -30,018 | -33,970 | -63,344 | -8,331 |
Net Change In Cash | 1,028 | 0 | 0 | 2,717 |
Cost of Revenue | -89,946 | |||
Free Cash Flow | -35,764 | -52,465 | -48,134 | -32,751 |
Cash | 3,762 | 5,864 | 27,007 | 117,453 |
Basic Shares | 28,476 | 25,505 | 23,817 | 19,712 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.18 |
2025-03-31 | -$0.27 |
2024-12-31 | -$0.27 |
